King's College London

Research portal

Associating Violence With Schizophrenia - Risks and Biases

Research output: Contribution to journalLetterpeer-review

Paolo Fusar-Poli, Charlene Sunkel, Vikram Patel

Original languageEnglish
Pages (from-to)738-739
Number of pages2
JournalJAMA Psychiatry
Volume79
Issue number7
DOIs
Accepted/In press2022
PublishedJul 2022

Bibliographical note

Funding Information: EMA Wellness, Engrail Therapeutics, Clexio, Denovo Biopharma, Gilgamesh, Hoffmann La-Roche, Intra-Cellular Therapies, Janssen Pharmaceuticals, Levo, Lundbeck, Merck, Navitor Pharmaceuticals, Neurocrine, Novartis, Noven Pharmaceuticals, Otsuka, Perception Neuroscience, Praxis Therapeutics, Sage Pharmaceuticals, Servier Pharmaceuticals, Seelos Pharmaceuticals, Taisho Pharmaceuticals, Teva, Valeant, Vistagen Therapeutics, and XW Labs. Dr Sanacora also reported receiving research contracts from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, and Usona over the past 36 months. Dr. Sanacora holds equity in Biohaven Pharmaceuticals and is a co-inventor on a US patent (8,778,979) held by Yale University and a co-inventor on US Provisional Patent Application 047162-7177P1 (00754) filed on August 20, 2018, by the Yale University Office of Cooperative Research. Yale University has a financial relationship with Janssen Pharmaceuticals and may in the future receive financial benefits from this relationship. The university has put multiple measures in place to mitigate this institutional conflict of interest. Questions about the details of these measures should be directed to Yale University’s Conflict of Interest office. Dr Wilkinson reported receiving contract funding from Janssen Pharmaceuticals, Sage Therapeutics, and Oui Therapeutics for the conduct of clinical trials administered through Yale University as well as consulting fees from Biohaven Pharmaceuticals, Sage Therapeutics, Janssen Pharmaceuticals, and Oui Therapeutics. No other disclosures were reported. Funding Information: Funding/Support: There was no direct funding for this study. However, the Yale Psychiatric Hospital provided indirect funding that allowed the Interventional Psychiatric Service to treat patients with ketamine in a clinical setting before most third-party payers began reimbursing for this service. In addition, funding through support was provided in part by the George D. Gross and Esther S. Gross Endowment (Dr Sanacora) and the Yale New Haven Health System (Drs Nikayin, Sanacora, and Wilkinson).

King's Authors

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454